Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine k...

Descripción completa

Detalles Bibliográficos
Autores principales: Gobin, Bérengère, Moriceau, Gatien, Ory, Benjamin, Charrier, Céline, Brion, Régis, Blanchard, Frederic, Redini, Françoise, Heymann, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944320/
https://www.ncbi.nlm.nih.gov/pubmed/24599309
http://dx.doi.org/10.1371/journal.pone.0090795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944320/
https://www.ncbi.nlm.nih.gov/pubmed/24599309
http://dx.doi.org/10.1371/journal.pone.0090795

Ejemplares similares